A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants

NCT06704763 · Completed

Last updated 2026-05-28

This clinical trial tested how the diabetes medication orforglipron interacts with the heart medication quinidine in healthy adults by measuring how the body processes each drug.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) basic-science study

Participants 27 people

Who can join Ages 21–70 · all sexes Healthy volunteers accepted.

Timeline Started 2024-12 · est. completion 2025-02

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06704763 ↗

Description as written by the study sponsor.

The purpose of this study is to determine the effect of quinidine on the levels of orforglipron in the blood stream and how long it takes the body to eliminate it, when administered orally in healthy participants. The study will last up to approximately 8 weeks including screening.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally
Midazolam Drug

Administered orally
Quinidine Drug

Administered orally

Main thing measured	Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Orforglipron
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06704763 ↗